Cargando…

Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment

BACKGROUND: Determination of HIV-1 tropism is a pre-requisite to the use of CCR5 antagonists. This study evaluated the potential of population genotypic tropism tests (GTTs) in clinical practice, and the correlation with phenotypic tropism tests (PTTs) in patients accessing routine HIV care. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vandekerckhove, Linos, Verhofstede, Chris, Demecheleer, Els, De Wit, Stephane, Florence, Eric, Fransen, Katrien, Moutschen, Michel, Mostmans, Wendy, Kabeya, Kabamba, Mackie, Nicola, Plum, Jean, Vaira, Dolores, Van Baelen, Kurt, Vandenbroucke, Ina, Van Eygen, Veerle, Van Marck, Herwig, Vogelaers, Dirk, Geretti, Anna Maria, Stuyver, Lieven J
Formato:	Texto
Lenguaje:	English
Publicado:	Oxford University Press 2011
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3019088/ https://www.ncbi.nlm.nih.gov/pubmed/21196489 http://dx.doi.org/10.1093/jac/dkq458

Ejemplares similares

HIV-1 V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays
por: Vandenbroucke, Ina, et al.
Publicado: (2010)

Minor Variant Detection at Different Template Concentrations in HIV-1 Phenotypic and Genotypic Tropism Testing
por: Vandenbroucke, Ina, et al.
Publicado: (2008)

Epidemiological study of phylogenetic transmission clusters in a local HIV-1 epidemic reveals distinct differences between subtype B and non-B infections
por: Chalmet, Kristen, et al.
Publicado: (2010)

Frequency and Predictors of HIV-1 Co-receptor Switch in Treatment Naive Patients
por: Mortier, Virginie, et al.
Publicado: (2013)

Comparison of Methods for In-House Screening of HLA-B*57:01 to Prevent Abacavir Hypersensitivity in HIV-1 Care
por: De Spiegelaere, Ward, et al.
Publicado: (2015)

Factors associated with the continuum of care of HIV-infected patients in Belgium
por: Van Beckhoven, Dominique, et al.
Publicado: (2014)

Consensus statement of the European guidelines on clinical management of HIV-1 tropism testing
por: Vandekerckhove, LPR, et al.
Publicado: (2010)

Parameters Influencing Baseline HIV-1 Genotypic Tropism Testing Related to Clinical Outcome in Patients on Maraviroc
por: Sierra, Saleta, et al.
Publicado: (2015)

Phenotypic co-receptor tropism and Maraviroc sensitivity in HIV-1 subtype C from East Africa
por: Siddik, Abu Bakar, et al.
Publicado: (2018)

Patient-reported outcomes among people living with HIV on single- versus multi-tablet regimens: Data from a real-life setting
por: Degroote, Sophie, et al.
Publicado: (2022)

Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48-week analysis of the PROTEST study
por: Garcia, Federico, et al.
Publicado: (2014)

Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials
por: Jubb, Becky, et al.
Publicado: (2019)

Population and ultra-deep sequencing for tropism determination are correlated with Trofile ES: genotypic re-analysis of the A4001078 maraviroc study
por: Portsmouth, S, et al.
Publicado: (2010)

Late presentation to HIV testing is overestimated when based on the consensus definition
por: Sasse, A, et al.
Publicado: (2015)

Clinical application of genotypic co-receptor tropism testing from viral RNA and proviral DNA: week 24 analysis of the Berlin maraviroc cohort
por: Obermeier, MJ, et al.
Publicado: (2010)

First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERN
por: Heera, Jayvant, et al.
Publicado: (2014)

Comparison of Droplet Digital PCR and Seminested Real-Time PCR for Quantification of Cell-Associated HIV-1 RNA
por: Kiselinova, Maja, et al.
Publicado: (2014)

Characterization of LEDGF/p75 Genetic Variants and Association with HIV-1 Disease Progression
por: Messiaen, Peter, et al.
Publicado: (2012)

Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey
por: De Luca, Andrea, et al.
Publicado: (2019)

Maraviroc in the treatment of HIV infection
por: Ray, Neelanjana
Publicado: (2009)

Maraviroc – A CCR5 Antagonist for the Treatment of HIV-1 Infection
por: Van Der Ryst, Elna
Publicado: (2015)

A7 Co-receptor tropism determined by genotypic assay in HIV-1 non-B subtypes circulating in Cuba: Implications for pathogenesis and Maraviroc resistance
por: Méndez, M, et al.
Publicado: (2019)

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: Analysis of the HIV-2 Belgium and Luxembourg database
por: Ruelle, Jean, et al.
Publicado: (2008)

A Synthetic HIV-1 Subtype C Backbone Generates Comparable PR and RT Resistance Profiles to a Subtype B Backbone in a Recombinant Virus Assay
por: Nauwelaers, David, et al.
Publicado: (2011)

Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study
por: Jesús Pérez Elías, María, et al.
Publicado: (2014)

Identification of three immunodominant motifs with atypical isotype profile scattered over the Onchocerca volvulus proteome
por: Lagatie, Ole, et al.
Publicado: (2017)

Maraviroc: the evidence for its potential in the management of HIV
por: Profit, Louise
Publicado: (2007)

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients
por: Gonzalez-Serna, Alejandro, et al.
Publicado: (2016)

Circulating human microRNAs are not linked to JC polyomavirus serology or urinary viral load in healthy subjects
por: Lagatie, Ole, et al.
Publicado: (2014)

Viral miRNAs in plasma and urine divulge JC polyomavirus infection
por: Lagatie, Ole, et al.
Publicado: (2014)

Antibodies reacting with JCPyV_VP2 _167-15mer as a novel serological marker for JC polyomavirus infection
por: Lagatie, Ole, et al.
Publicado: (2014)

Quasispecies Analysis of JC Virus DNA Present in Urine of Healthy Subjects
por: Van Loy, Tom, et al.
Publicado: (2013)

Implications of maraviroc and/or rapamycin in a mouse model of fragility
por: Pérez-Martínez, Laura, et al.
Publicado: (2020)

An antibody response to human polyomavirus 15-mer peptides is highly abundant in healthy human subjects
por: Stuyver, Lieven J, et al.
Publicado: (2013)

Droplet digital PCR is an accurate method to assess methylation status on FFPE samples
por: Van Wesenbeeck, Liesbeth, et al.
Publicado: (2018)

Impact of coronavirus pandemic and containment measures on HIV diagnosis
por: Darcis, Gilles, et al.
Publicado: (2020)

Measuring Proviral HIV-1 DNA: Hurdles and Improvements to an Assay Monitoring Integration Events Utilising Human Alu Repeat Sequences
por: Malatinkova, Eva, et al.
Publicado: (2021)

On the whereabouts of SARS-CoV-2 in the human body: A systematic review
por: Trypsteen, Wim, et al.
Publicado: (2020)

Evaluating lncRNA Expression Patterns during HIV-1 Treatment Interruption
por: Schynkel, Tinus, et al.
Publicado: (2023)

The role of diagnostic technologies to measure progress toward WHO 2030 targets for soil-transmitted helminth control programs
por: Stuyver, Lieven J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mguh7jcamgjls88ageudpg89gu